Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

November 10, 2022

Study Completion Date

November 17, 2022

Conditions
Lassa Fever
Interventions
DRUG

Ribavirin iv

100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10

DRUG

Favipiravir

Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily

Trial Locations (2)

Unknown

Irrua Specialist Teaching Hospital, Irrua

Federal Medical Center of Owo, Owo

All Listed Sponsors
collaborator

University of Hamburg-Eppendorf

OTHER

collaborator

Alliance for International Medical Action

OTHER

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

University of Bordeaux

OTHER

collaborator

Federal Medical Centre, Owo

INDUSTRY

collaborator

Irrua Specialist Teaching Hospital

OTHER

lead

Bernhard Nocht Institute for Tropical Medicine

OTHER_GOV

NCT04907682 - Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever | Biotech Hunter | Biotech Hunter